Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study.

Pitter JG, Csanádi M, Szigeti A, Lukács G, Kovács Á, Moizs M, Repa I, Zemplényi A, Czypionka T, Kraus M, Rutten-van Mölken MPMH, Kaló Z.

BMC Health Serv Res. 2019 Feb 21;19(1):131. doi: 10.1186/s12913-019-3957-9.

2.

Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

Németh B, Molnár A, Bozóki S, Wijaya K, Inotai A, Campbell JD, Kaló Z.

J Comp Eff Res. 2019 Mar;8(4):195-204. doi: 10.2217/cer-2018-0102. Epub 2019 Feb 15.

3.

Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review.

Szilberhorn L, Kaló Z, Ágh T.

Antivir Ther. 2019 Jan 16. doi: 10.3851/IMP3290. [Epub ahead of print]

PMID:
30652971
4.

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.

Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, Yasmina A, Priohutomo S, Németh B, Wijaya K, Kalo Z.

BMC Health Serv Res. 2018 Dec 29;18(1):1003. doi: 10.1186/s12913-018-3805-3.

5.

Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

Inotai A, Ágh T, Karpenko AW, Zemplényi A, Kaló Z.

Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):105-113. doi: 10.1080/14737167.2019.1554437. Epub 2018 Dec 7. Review.

PMID:
30488730
6.

The European challenges of funding orphan medicinal products.

Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Fürst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister-Koss I, Kaló Z, Molnár MJ.

Orphanet J Rare Dis. 2018 Nov 6;13(1):184. doi: 10.1186/s13023-018-0927-y.

7.

A systematic review of the indirect costs of schizophrenia in Europe.

Fasseeh A, Németh B, Molnár A, Fricke FU, Horváth M, Kóczián K, Götze Á, Kaló Z.

Eur J Public Health. 2018 Dec 1;28(6):1043-1049. doi: 10.1093/eurpub/cky231.

8.

Fair global drug pricing.

Campbell JD, Kaló Z.

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):581-583. doi: 10.1080/14737167.2018.1524296. Epub 2018 Sep 28. No abstract available.

PMID:
30215535
9.

Guidance toward the implementation of multicriteria decision analysis framework in developing countries.

Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Németh B, Maniadakis N, Brixner D, Wijaya K, Kaló Z.

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592. doi: 10.1080/14737167.2018.1508345. Epub 2018 Aug 24.

PMID:
30092151
10.

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.

Kamusheva M, Manova M, Savova AT, Petrova GI, Mitov K, Harsányi A, Kaló Z, Márky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganic P, Geitona M, Hatzikou M, Paveliu MS, Männik A.

Front Pharmacol. 2018 Jul 20;9:795. doi: 10.3389/fphar.2018.00795. eCollection 2018.

11.

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, Morel T, Simoens S, Kaló Z, Gatermann R, Redekop W.

Value Health. 2018 May;21(5):493-500. doi: 10.1016/j.jval.2018.03.004. Epub 2018 Apr 11.

PMID:
29753344
12.

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.

Kolasa K, Zwolinski KM, Zah V, Kaló Z, Lewandowski T.

Orphanet J Rare Dis. 2018 Apr 27;13(1):67. doi: 10.1186/s13023-018-0803-9.

13.

Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries.

Van Hout MC, Benschop A, Bujalski M, Dąbrowska K, Demetrovics Z, Felvinczi K, Hearne E, Henriques S, Kaló Z, Kamphausen G, Korf D, Silva JP, Wieczorek Ł, Werse B.

Int J Ment Health Addict. 2018;16(2):480-495. doi: 10.1007/s11469-017-9824-1. Epub 2017 Dec 7.

14.

An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.

Brixner D, Kaló Z, Maniadakis N, Kim K, Wijaya K.

Value Health Reg Issues. 2018 Sep;16:9-13. doi: 10.1016/j.vhri.2018.01.003. Epub 2018 Mar 30.

PMID:
29605800
15.

When health technology assessment is confidential and experts have no power: the case of Hungary.

Csanádi M, Löblová O, Ozierański P, Harsányi A, Kaló Z, McKee M, King L.

Health Econ Policy Law. 2019 Apr;14(2):162-181. doi: 10.1017/S1744133118000051. Epub 2018 Mar 26.

PMID:
29576025
16.

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.

Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z.

Biomed Res Int. 2018 Jan 10;2018:9597362. doi: 10.1155/2018/9597362. eCollection 2018.

17.

Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study.

Kulchaitanaroaj P, Kaló Z, West R, Cheung KL, Evers S, Vokó Z, Hiligsmann M, de Vries H, Owen L, Trapero-Bertran M, Leidl R, Pokhrel S.

BMC Health Serv Res. 2018 Feb 14;18(1):115. doi: 10.1186/s12913-018-2923-2.

18.

Direct healthcare cost of schizophrenia - European overview.

Kovács G, Almási T, Millier A, Toumi M, Horváth M, Kóczián K, Götze Á, Kaló Z, Zemplényi AT.

Eur Psychiatry. 2018 Feb;48:79-92. doi: 10.1016/j.eurpsy.2017.10.008. Epub 2018 Feb 3. Review.

PMID:
29428166
19.

A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study.

Németh B, Kulchaitanaroaj P, Lester-George A, Huic M, Coyle K, Coyle D, Pokhrel S, Kaló Z.

Addiction. 2018 Jun;113 Suppl 1:42-51. doi: 10.1111/add.14092. Epub 2018 Jan 28.

20.

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer.

Tesar T, Szilberhorn L, Nemeth B, Nagy B, Wawruch M, Kalo Z.

Front Pharmacol. 2017 Dec 22;8:946. doi: 10.3389/fphar.2017.00946. eCollection 2017.

Supplemental Content

Support Center